Nureca Limited operates in consumer healthcare and home-healthcare products, including equipment and devices used for wellness, monitoring and home medical care. Its business benefits from increasing health awareness and adoption of home-based healthcare solutions. E-commerce, product expansion and growing consumer healthcare spending provide opportunities. Consumer demand, product quality, regulatory requirements, inventory management and competition remain important factors.
| Market cap | Sales (TTM) | Net profit (TTM) | P/E | EPS (TTM) | P/B | ROE | ROE previous year | ROCE | Debt / equity | Free cash flow | EV / EBITDA | Beta |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹299 cr | ₹187 cr | ₹5 cr | 61.3 | 5.11 | 1.65 | 1.1% | 0.4% | 3.3% | 0.00 | ₹-3 cr | 36.9 | 1.07 |
| Quarter | Sales ₹ cr | Net profit ₹ cr | EPS | EPS YoY | Sales YoY | Net margin |
|---|---|---|---|---|---|---|
| Jun 2026 | 40 | 3 | 3.21 | +296.3% | +18.0% | 7.6% |
| Mar 2026 | 35 | -6 | -6.45 | -361.1% | +11.6% | -17.2% |
| Dec 2025 | 40 | 4 | 3.91 | turnaround | +49.8% | 9.4% |
| Sep 2025 | 72 | 4 | 4.44 | turnaround | +130.6% | 6.2% |
| Jun 2025 | 34 | 1 | 0.81 | -51.2% | +68.6% | 2.4% |
| Mar 2025 | 32 | 2 | 2.47 | turnaround | +87.0% | 7.8% |
| Dec 2024 | 26 | -3 | -2.80 | -1850.0% | +18.3% | -10.6% |
| Sep 2024 | 31 | -0 | -0.48 | -116.5% | -0.5% | -1.6% |
| Check | Result |
|---|---|
| Latest quarter EPS up 25%+ on a year ago | ✓ Pass |
| EPS growth accelerating over 3 quarters | — Not assessable |
| Sales up 25%+, or sales growth accelerating | ✗ Fail |
| Annual EPS up 25%+ in each of the last 2 years | — Not assessable |
| Net margin above the same quarter last year | ✓ Pass |
| Method | Checks | Score | Verdict |
|---|---|---|---|
| Minervini | ✓ Close above the 150- and 200-day averages ✗ 150-day above 200-day ✓ 200-day rising for a month ✓ 50-day above the 150- and 200-day ✗ Close above the 50-day ✓ At least 25% above the 52-week low · low 206.75 ✓ Within 25% of the 52-week high · high 366.60 ✓ RS percentile 70 or more · RS 82 Trend template - the gate, measured: a modest 21-day edge. | 6/8 | 6 of 8 |
| Weinstein | Stan Weinstein's stage analysis on the 30-week moving average. | Stage 2 - advancing | |
| CAN SLIM | ✓ C latest quarter EPS up 25%+ — A annual EPS up 25%+ in each of the last 2 years · O'Neil asks 3; ~2 held ✓ N within 15% of the 52-week high · high 366.60 ✓ S more volume on up days than down days (50 sessions) · 1.28x ✓ L RS percentile 80 or more · RS 82 — I institutional sponsorship rising · shareholding not collected yet ✓ M market in an uptrend (40%+ of stocks above their 200-day) · breadth 45% William O'Neil's growth-leader checklist. | 5/5 | Strong |
| Darvas | ✓ Box top confirmed (3 sessions below the new high) · top 376.00 ✗ Box bottom confirmed (3 sessions holding) · bottom 319.00 ✗ Close above the box top · close 313.25 ✗ Volume at least 1.5x its 50-day average · 0.3x Nicolas Darvas's box: buy the breakout above a confirmed box after a new high. | 44/100 | In box |
| Turtle | ✗ Close above the prior 55-session high · 376.00 ✗ Close above the prior 20-session high · 376.00 ✓ Close below the prior 20-session low · 319.00 Donchian channel breakout - the Turtle traders' entry. | Breakdown | |
| Greenblatt | — Earnings yield (EBITDA / EV) · 2.7% — Return on capital (ROCE) · 3.3% Joel Greenblatt's Magic Formula: good businesses at good prices, ranked across all companies. Earnings yield uses EBITDA, as EBIT is not held separately. | 5/100 | Weak |
| Graham | ✗ Price at or below the Graham number · Graham number 147.74 ✗ P/E 15 or less · P/E 61.3 ✗ P/B 1.5 or less (or P/E x P/B 22.5 or less) · P/B 1.65 ✓ Current ratio 2 or more · 8.32 — 10 years of positive earnings, 20 of dividends · history not held Benjamin Graham's defensive-investor tests. | 47/100 | Expensive |
| Piotroski | ✓ Profitable (ROA > 0) ✓ Operating cash flow positive ✓ ROA rising ✓ Cash flow above net profit (earnings quality) ✓ Long-term debt / assets falling ✗ Current ratio rising · 8.32 ✓ No new shares issued ✓ Margin rising (net margin) ✓ Asset turnover rising Joseph Piotroski's F-score, FY 2025 -> 2026. | 8/9 | Strong |
| Stock | 1M % | 3M % | 6M % | 1Y % | 3Y % | 5Y % | P/E | P/B | ROE % | ROCE % | ROA % | D/E | EV/EBITDA | ₹ Cr | Sales TTM ₹ Cr | Profit TTM ₹ Cr | EPS | Beta |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NURECA this stock | -9.4 | +10.9 | +20.7 | +8.3 | -13.6 | -82.8 | 61.3 | 1.65 | 1.1 | 3.3 | — | 0.00 | 36.9 | 299 | 187 | 5 | 5.1 | 1.07 |
| SHAILY | -1.4 | +8.7 | +68.2 | +30.0 | +747.9 | — | 65.5 | 19.93 | 26.9 | 29.3 | — | 0.24 | 50.2 | 14,284 | 1,271 | 218 | 47.4 | 0.51 |
| TARSONS | +3.0 | +12.1 | +48.2 | +8.4 | -36.2 | — | 150.8 | 2.64 | 2.3 | 4.5 | — | 0.60 | 15.1 | 1,677 | 441 | 11 | 2.1 | 1.15 |
| MOHEALTH | -6.6 | -5.1 | +10.5 | +6.8 | +68.5 | — | — | — | — | — | — | — | — | — | — | — | — | 0.58 |
| POLYMED | -10.2 | -9.9 | +6.5 | -18.6 | +12.4 | +64.4 | 49.9 | 5.06 | 11.0 | 13.7 | — | 0.11 | 29.6 | 15,718 | 1,997 | 313 | 31.1 | 0.91 |
| GLOTTIS | -8.6 | -17.8 | -3.1 | -23.9 | — | — | 13.4 | 1.79 | 13.7 | — | — | 0.18 | 9.9 | 503 | — | — | 4.2 | 0.98 |
| AMRUTANJAN | +1.1 | -8.7 | -8.3 | -30.8 | -16.9 | -46.4 | 26.7 | 3.90 | 16.6 | 22.4 | — | 0.00 | 17.5 | 1,443 | 512 | 54 | 18.7 | 0.51 |
| LAXMIDENTL | -8.2 | -18.9 | -6.0 | -42.1 | — | — | 32.1 | 4.11 | 12.8 | 13.1 | — | 0.00 | 21.8 | 999 | 287 | 31 | 5.7 | 1.19 |